DAX24.672 -2,4%Est505.992 -2,4%MSCI World4.343 -0,1%Top 10 Crypto8,8700 +6,5%Nas22.778 +0,5%Bitcoin58.783 +5,2%Euro1,1702 -0,6%Öl77,67 +7,1%Gold5.333 +1,1%
Beliebte Suche
DAX 40 Ölpreis Euro - Dollar Bitcoin - Euro Goldpreis
Meistgesucht
freenet A0Z2ZZ AIXTRON A0WMPJ E.ON ENAG99 Münchener Rückversicherungs-Gesellschaft 843002 Heidelberg Materials 604700 Tesla A1CX3T Vonovia A1ML7J BioNTech (ADRs) A2PSR2 NEL ASA A0B733 AMD (Advanced Micro Devices) 863186 RWE 703712 Airbus 938914 Rolls-Royce A1H81L TKMS thyssenkrupp Marine Systems TKMS00 Micron Technology 869020
Alle Aktien für 0 Euro (zzgl. Spreads) handeln mit finanzen.net zero. Hier informieren
Heute im Fokus
Nahostkonflikt: DAX fällt deutlich unter 25.000 -- US-Börsen uneins -- Kurspotenzial bei Rheinmetall & Co.? -- Lufthansa und TUI im Sinkflug -- Almonty, Palantir, Trump Media, Öl, Goldpreis im Fokus
Top News
Auf dem Verkaufszettel: Diese Aktien empfehlen Experten zu verkaufen Auf dem Verkaufszettel: Diese Aktien empfehlen Experten zu verkaufen
Februar tiefroter Krypto-Monat: Das hat Bitcoin, Ethereum & Co. belastet - Die weiteren Aussichten Februar tiefroter Krypto-Monat: Das hat Bitcoin, Ethereum & Co. belastet - Die weiteren Aussichten
Suche...
Login
ODER

Neu auf finanzen.net?

Kostenfrei registrieren und Vorteile nutzen

Übersicht Wertpapierdepots Musterdepots Watchlists Meine News Newsletter Forum Trading Desk Apps Social Media Podcasts
Profil

Vanda Pharmaceuticals Aktie

Kaufen
Verkaufen
Aktien-Sparplan anlegen
6,95 EUR -0,50 EUR -6,71 %
STU
8,19 USD -0,73 USD -8,18 %
BTT
Vanda Pharmaceuticals jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)
Smartphone

Marktkap.449,86 Mio. EUR

Div. Rendite0,00%
WKN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

WKNA0JJT3

ISIN wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

ISINUS9216591084

Symbol wurde kopiert
NEU
Handle jetzt direkt über finanzen.net mit Deinem Broker
Direkt handeln

SymbolVNDA

Vanda Pharmaceuticals Aktien News

DatumMeistgelesen
PR NewswireVanda Pharmaceuticals Announces Receipt of FDA Decision Letter on HETLIOZ® Supplemental New Drug Application for Jet Lag Disorder
PR NewswireVanda Pharmaceuticals Announces FDA Approval of NEREUS™ (tradipitant) for the Prevention of Vomiting Induced by Motion: A Historic Scientific Milestone in the Prevention of Motion Sickness
PR NewswireVanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis
Wer­bungVanda Pharmaceuticals-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero
PR NewswireVanda Pharmaceuticals Announces Participation in the J.P. Morgan Healthcare Conference
PR NewswireFDA Lifts Partial Clinical Hold on Tradipitant for Motion Sickness
PR NewswireVanda Pharmaceuticals Provides Regulatory Update on Tradipitant for Motion Sickness
PR NewswireVanda Pharmaceuticals Reports Positive Results for Tradipitant in Preventing GLP-1 Induced Nausea and Vomiting
PR NewswireVanda Pharmaceuticals Announces Participation in the Stifel 2025 Healthcare Conference
PR NewswireVanda Pharmaceuticals Reports Third Quarter 2025 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Third Quarter 2025 Financial Results on October 29, 2025
PR NewswireMonumental Sports & Entertainment Taps D.C.'s Own Vanda Pharmaceuticals as Founding Partner to Help Drive the Creation of Brand-New Downtown Arena
PR NewswireVanda Pharmaceuticals announces the publication in PLOS One of an article titled "Melatonin agonist tasimelteon (HETLIOZ®) improves sleep in patients with primary insomnia: A multicenter, randomiz...
PR NewswireVanda Pharmaceuticals Announces Participation at September 2025 Investor Conferences
PR NewswireVanda Pharmaceuticals Announces FDA Granted Orphan Drug Designation for VGT-1849B, a Novel and Selective Candidate for the Treatment of Polycythemia Vera
PR NewswireVanda Pharmaceuticals Reports Second Quarter 2025 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Second Quarter 2025 Financial Results on July 31, 2025
PR NewswireVanda Pharmaceuticals Announces First Patient Dosed in a Trial Evaluating VCA-894A in Charcot-Marie-Tooth disease Type 2S
PR NewswireVanda Pharmaceuticals Announces Presentation at 2025 ASCP Annual Meeting
PR NewswireVanda Pharmaceuticals Announces Participation in the Mizuho Neuro & Ophthalmology Summit 2025
PR NewswireVanda Pharmaceuticals Reports First Quarter 2025 Financial Results
PR NewswireVanda Announces Bysanti™ NDA Filing; FDA Decision Expected in Early 2026
PR NewswireVanda Pharmaceuticals to Announce First Quarter 2025 Financial Results on May 7, 2025
PR NewswireVanda Pharmaceuticals Announces Presentation at 2025 AAN Annual Meeting
PR NewswireVanda Pharmaceuticals Announces the Submission of an NDA to the FDA for Bysanti™ for the Treatments of Acute Bipolar I Disorder and Schizophrenia
PR NewswireVanda Pharmaceuticals announces the publication of an article titled "Potential ASO-based personalized treatment for Charcot-Marie-Tooth disease type 2S"
PR NewswireVanda Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results
PR NewswireVanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on February 13, 2025
PR NewswireVanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
PR NewswireVanda Pharmaceuticals Accepts FDA Opportunity for a Hearing on New Drug Application for Tradipitant in Gastroparesis
PR NewswireVanda's Letter to FDA Commissioner Highlights Faulty Gastroparesis NDA Review
PR NewswireVanda Pharmaceuticals Announces Orphan Drug Designation Granted for VGT-1849A, a Novel and Selective Antisense Oligonucleotide Candidate for the Treatment of Polycythemia Vera
PR NewswireVanda Pharmaceuticals Announces Participation at November 2024 Investor Conferences
PR NewswireVanda Pharmaceuticals Reports Third Quarter 2024 Financial Results
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
PR NewswireVanda Pharmaceuticals to Announce Third Quarter 2024 Financial Results on November 6, 2024
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
PR NewswireVanda Pharmaceuticals Confirms Receipt of Economically Identical Unsolicited, Non-Binding Proposal from Cycle Group Holdings Ltd.
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
PR NewswireSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Vanda Pharmaceuticals Inc. - VNDA
PR NewswireFDA Declines to Approve Vanda's Marketing Application for Tradipitant in Gastroparesis

Vanda Pharmaceuticals News

Vanda Pharmaceuticals News: auf dieser Seite finden Sie alle Vanda Pharmaceuticals News und Nachrichten zur Vanda Pharmaceuticals Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Vanda Pharmaceuticals News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Vanda Pharmaceuticals News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.